Rani Therapeutics Holdings Inc (RANI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rani Therapeutics Holdings Inc stock (RANI) is currently trading at $1.14. Rani Therapeutics Holdings Inc PS ratio (Price-to-Sales) is 116.51. Analyst consensus price target for RANI is $8.00. WallStSmart rates RANI as Sell.
- RANI PE ratio analysis and historical PE chart
- RANI PS ratio (Price-to-Sales) history and trend
- RANI intrinsic value — DCF, Graham Number, EPV models
- RANI stock price prediction 2025 2026 2027 2028 2029 2030
- RANI fair value vs current price
- RANI insider transactions and insider buying
- Is RANI undervalued or overvalued?
- Rani Therapeutics Holdings Inc financial analysis — revenue, earnings, cash flow
- RANI Piotroski F-Score and Altman Z-Score
- RANI analyst price target and Smart Rating
Rani Therapeutics Holdings Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Rani Therapeutics Holdings Inc (RANI) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Rani Therapeutics Holdings Inc (RANI) Key Strengths (1)
50.63% held by institutions, strong professional interest
Supporting Valuation Data
Rani Therapeutics Holdings Inc (RANI) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 116.5x annual revenue
Very expensive at 23.9x book value
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Rani Therapeutics Holdings Inc (RANI) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (116.51), Price/Book (23.87) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -1188.00%, Operating Margin at -3418.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1188.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RANI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RANI's Price-to-Sales ratio of 116.51x trades at a deep discount to its historical average of 489.35x (27th percentile). The current valuation is 98% below its historical high of 6492.84x set in Nov 2021, and 156% above its historical low of 45.55x in Sep 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rani Therapeutics Holdings Inc (RANI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Rani Therapeutics Holdings Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1M with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of -2.23 indicates a conservative balance sheet with 4M in cash.
Spending 268% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Debt management: total debt of 18M is significantly higher than cash (4M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Rani Therapeutics Holdings Inc.
Bottom Line
Rani Therapeutics Holdings Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Rani Therapeutics Holdings Inc(RANI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company focused on transforming the delivery of injectable therapeutics with its cutting-edge RaniPill™ technology, facilitating the oral administration of biologics. This proprietary platform is designed to enhance patient adherence and improve treatment outcomes, addressing key unmet needs in the healthcare sector. With a robust and diverse pipeline across various therapeutic areas, Rani Therapeutics is poised to disrupt traditional drug delivery systems while capitalizing on the growing demand for non-invasive alternatives. The company’s strategic partnerships and unwavering commitment to research and development underscore its potential for sustainable growth and significant impact within the pharmaceutical industry.